A5091187730- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Computational Drug Discovery Methods
- Graphene and Nanomaterials Applications
- Nanoparticle-Based Drug Delivery
- Cancer Treatment and Pharmacology
- Silicon Carbide Semiconductor Technologies
- Inflammatory Biomarkers in Disease Prognosis
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- CAR-T cell therapy research
- Colorectal and Anal Carcinomas
- HER2/EGFR in Cancer Research
- Advancements in Semiconductor Devices and Circuit Design
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
- Lymphoma Diagnosis and Treatment
National Center for Nanoscience and Technology
2023-2024
University of Chinese Academy of Sciences
2024
Peking University
2023
Peking University Cancer Hospital
2023
Tsinghua University
2023
Nanoparticles (NP) spanning diverse materials and properties have the potential to encapsulate protect a wide range of therapeutic cargos increase bioavailability, prevent undesired degradation, mitigate toxicity. Fulvestrant, selective estrogen receptor degrader, is commonly used for treating patients with (ER)-positive breast cancer, but its broad continual application limited by poor solubility, invasive muscle administration, drug resistance. Here, we developed an active targeting...
Despite its significant clinical efficacy as a first-line treatment for advanced bladder cancer, cisplatin-based chemotherapy provides limited benefit patients with lymphovascular invasion (LVI), which is characterized by the presence of tumor emboli within blood vessels and associated enhanced cisplatin resistance metastatic potential. Notably, platelets, critical component LVI, hinder delivery chemotherapeutic agents to tumors facilitate metastasis. Consequently, platelet function...
<p>Supporting information for manuscript</p>
<p>Supporting information for manuscript</p>
<div>Abstract<p>Nanoparticles (NPs) spanning diverse materials and properties have the potential to encapsulate protect a wide range of therapeutic cargos increase bioavailability, prevent undesired degradation, mitigate toxicity. Fulvestrant, selective estrogen receptor degrader (SERD), is commonly used for treating (ER)-positive breast cancer patients, but its broad continual application limited by poor solubility, invasive muscle administration, drug resistance. Here, we...
<div>Abstract<p>Nanoparticles (NPs) spanning diverse materials and properties have the potential to encapsulate protect a wide range of therapeutic cargos increase bioavailability, prevent undesired degradation, mitigate toxicity. Fulvestrant, selective estrogen receptor degrader (SERD), is commonly used for treating (ER)-positive breast cancer patients, but its broad continual application limited by poor solubility, invasive muscle administration, drug resistance. Here, we...
<p>Supporting information for manuscript</p>
<div>Abstract<p>Nanoparticles (NP) spanning diverse materials and properties have the potential to encapsulate protect a wide range of therapeutic cargos increase bioavailability, prevent undesired degradation, mitigate toxicity. Fulvestrant, selective estrogen receptor degrader, is commonly used for treating patients with (ER)–positive breast cancer, but its broad continual application limited by poor solubility, invasive muscle administration, drug resistance. Here, we...
<p>Supporting information for manuscript</p>